甲基胺诱导的冠状动脉和经常性心脏骤停:一眼可能不够好
Ramtin Khanipour1, Kevin Velasquez1, Wesley Navaez1
1Division of Cardiology, HCA Healthcare-HCA Florida Bayonet Point/USF Morsani College of Medicine, Hudson, Florida, USA.
JACC. Case reports
|December 12, 2025
概括
甲基胺使用可以导致严重的冠状动脉,使心脏病的诊断复杂化. 在冠状动脉血管造影期间迅速使用血管扩展剂进行重新评估对于准确的病变检测和管理至关重要.
科学领域:
- 心脏病学 心脏病学
- 毒理学 毒理学 毒理学
背景情况:
- 甲基胺使用与冠状动脉,动脉硬性斑块破坏,心肌缺血和心电节律失常有关.
- 这一案例凸显了与甲基胺滥用有关的严重心血管并发症.
研究的目的:
- 在甲基胺使用者中呈现复发多态心室性心动减速和心脏骤停的病例.
- 为了强调甲基胺诱导的冠心血管所带来的诊断挑战.
主要方法:
- 一名51岁的男性患者有甲基胺使用史,出现了复发的多形心室性心动减速和心脏骤停.
- 最初的冠状动脉血管学显示了扩散的多血管疾病,导致推迟穿皮冠状动脉干预.
- 在急性心肌梗塞后重复冠状动脉扫描确定了一个单一的罪祸首病变,用药物释放支架治疗.
主要成果:
- 患者在使用甲基胺后经历了复发的多形心室性心动减速和心脏骤停.
- 最初的冠状动脉血管学发现因扩散性疾病而复杂化,掩盖了焦点罪祸首的病变.
- 随后的冠状动脉动图显示,在急性事件发生后,可治疗的损伤.
结论:
- 甲胺可以诱导显著的冠状动脉缩和内皮功能障碍,使得初始冠状动脉血管学难以识别罪祸首的病变.
- 在冠状动脉扫描期间使用血管扩展剂进行重新评估对于准确诊断和管理疑似甲基胺相关冠状动脉疾病至关重要.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
580
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
580
Coronary Artery Disease III: Clinical Manifestations
306
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
306
Acute Coronary Syndrome IV: Interprofessional Care
197
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
197
Acute Coronary Syndrome I: Introduction
711
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
711
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
325
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
325
Myocarditis III: Medical Management
160
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
160


